Cargando…
Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with 10-Valent or 13-Valent Pneumococcal Conjugate Vaccine: A Randomized Controlled Trial in Papua New Guinean Children
We investigated the immunogenicity, seroprotection rates and persistence of immune memory in young children at high risk of pneumococcal disease in Papua New Guinea (PNG). Children were primed with 10-valent (PCV10) or 13-valent pneumococcal conjugate vaccines (PCV13) at 1, 2 and 3 months of age and...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466212/ https://www.ncbi.nlm.nih.gov/pubmed/30720721 http://dx.doi.org/10.3390/vaccines7010017 |
_version_ | 1783411056558735360 |
---|---|
author | van den Biggelaar, Anita H. J. Pomat, William S. Masiria, Geraldine Wana, Sandra Nivio, Birunu Francis, Jacinta Ford, Rebecca Passey, Megan Kirkham, Lea-Ann Jacoby, Peter Lehmann, Deborah Richmond, Peter |
author_facet | van den Biggelaar, Anita H. J. Pomat, William S. Masiria, Geraldine Wana, Sandra Nivio, Birunu Francis, Jacinta Ford, Rebecca Passey, Megan Kirkham, Lea-Ann Jacoby, Peter Lehmann, Deborah Richmond, Peter |
author_sort | van den Biggelaar, Anita H. J. |
collection | PubMed |
description | We investigated the immunogenicity, seroprotection rates and persistence of immune memory in young children at high risk of pneumococcal disease in Papua New Guinea (PNG). Children were primed with 10-valent (PCV10) or 13-valent pneumococcal conjugate vaccines (PCV13) at 1, 2 and 3 months of age and randomized at 9 months to receive PPV (PCV10/PPV-vaccinated, n = 51; PCV13/PPV-vaccinated, n = 52) or no PPV (PCV10/PPV-naive, n = 57; PCV13/PPV-naive, n = 48). All children received a micro-dose of PPV at 23 months of age to study the capacity to respond to a pneumococcal challenge. PPV vaccination resulted in significantly increased IgG responses (1.4 to 10.5-fold change) at 10 months of age for all PPV-serotypes tested. Both PPV-vaccinated and PPV-naive children responded to the 23-month challenge and post-challenge seroprotection rates (IgG ≥ 0.35 μg/mL) were similar in the two groups (80–100% for 12 of 14 tested vaccine serotypes). These findings show that PPV is immunogenic in 9-month-old children at high risk of pneumococcal infections and does not affect the capacity to produce protective immune responses. Priming with currently available PCVs followed by a PPV booster in later infancy could offer improved protection to young children at high risk of severe pneumococcal infections caused by a broad range of serotypes. |
format | Online Article Text |
id | pubmed-6466212 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64662122019-04-18 Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with 10-Valent or 13-Valent Pneumococcal Conjugate Vaccine: A Randomized Controlled Trial in Papua New Guinean Children van den Biggelaar, Anita H. J. Pomat, William S. Masiria, Geraldine Wana, Sandra Nivio, Birunu Francis, Jacinta Ford, Rebecca Passey, Megan Kirkham, Lea-Ann Jacoby, Peter Lehmann, Deborah Richmond, Peter Vaccines (Basel) Article We investigated the immunogenicity, seroprotection rates and persistence of immune memory in young children at high risk of pneumococcal disease in Papua New Guinea (PNG). Children were primed with 10-valent (PCV10) or 13-valent pneumococcal conjugate vaccines (PCV13) at 1, 2 and 3 months of age and randomized at 9 months to receive PPV (PCV10/PPV-vaccinated, n = 51; PCV13/PPV-vaccinated, n = 52) or no PPV (PCV10/PPV-naive, n = 57; PCV13/PPV-naive, n = 48). All children received a micro-dose of PPV at 23 months of age to study the capacity to respond to a pneumococcal challenge. PPV vaccination resulted in significantly increased IgG responses (1.4 to 10.5-fold change) at 10 months of age for all PPV-serotypes tested. Both PPV-vaccinated and PPV-naive children responded to the 23-month challenge and post-challenge seroprotection rates (IgG ≥ 0.35 μg/mL) were similar in the two groups (80–100% for 12 of 14 tested vaccine serotypes). These findings show that PPV is immunogenic in 9-month-old children at high risk of pneumococcal infections and does not affect the capacity to produce protective immune responses. Priming with currently available PCVs followed by a PPV booster in later infancy could offer improved protection to young children at high risk of severe pneumococcal infections caused by a broad range of serotypes. MDPI 2019-02-04 /pmc/articles/PMC6466212/ /pubmed/30720721 http://dx.doi.org/10.3390/vaccines7010017 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article van den Biggelaar, Anita H. J. Pomat, William S. Masiria, Geraldine Wana, Sandra Nivio, Birunu Francis, Jacinta Ford, Rebecca Passey, Megan Kirkham, Lea-Ann Jacoby, Peter Lehmann, Deborah Richmond, Peter Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with 10-Valent or 13-Valent Pneumococcal Conjugate Vaccine: A Randomized Controlled Trial in Papua New Guinean Children |
title | Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with 10-Valent or 13-Valent Pneumococcal Conjugate Vaccine: A Randomized Controlled Trial in Papua New Guinean Children |
title_full | Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with 10-Valent or 13-Valent Pneumococcal Conjugate Vaccine: A Randomized Controlled Trial in Papua New Guinean Children |
title_fullStr | Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with 10-Valent or 13-Valent Pneumococcal Conjugate Vaccine: A Randomized Controlled Trial in Papua New Guinean Children |
title_full_unstemmed | Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with 10-Valent or 13-Valent Pneumococcal Conjugate Vaccine: A Randomized Controlled Trial in Papua New Guinean Children |
title_short | Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with 10-Valent or 13-Valent Pneumococcal Conjugate Vaccine: A Randomized Controlled Trial in Papua New Guinean Children |
title_sort | immunogenicity and immune memory after a pneumococcal polysaccharide vaccine booster in a high-risk population primed with 10-valent or 13-valent pneumococcal conjugate vaccine: a randomized controlled trial in papua new guinean children |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466212/ https://www.ncbi.nlm.nih.gov/pubmed/30720721 http://dx.doi.org/10.3390/vaccines7010017 |
work_keys_str_mv | AT vandenbiggelaaranitahj immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren AT pomatwilliams immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren AT masiriageraldine immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren AT wanasandra immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren AT niviobirunu immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren AT francisjacinta immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren AT fordrebecca immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren AT passeymegan immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren AT kirkhamleaann immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren AT jacobypeter immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren AT lehmanndeborah immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren AT richmondpeter immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren AT immunogenicityandimmunememoryafterapneumococcalpolysaccharidevaccineboosterinahighriskpopulationprimedwith10valentor13valentpneumococcalconjugatevaccinearandomizedcontrolledtrialinpapuanewguineanchildren |